The hematopoietic stem cell is a target for many gene therapy applications. However, stem cells with repopulating capacity have been largely resistant to gene transfer with amphotropic retroviral vectors, while the more mature clonogenic CD34
+ progenitor cells can be transduced efficiently. 1 One restriction of retroviral gene transfer into hematopoietic stem cells was found at the level of virus entry. Most retroviral vectors used for gene therapy carry the amphotropic envelope glycoprotein. Amphotropic virus Correspondence: D von Laer, Heinrich-Pette-Institut, Martinistr. 52, D-20251, Hamburg, Germany binds poorly to stem cells, most likely due to low expression of the amphotropic receptor Pit-2. [2] [3] [4] In recent studies, gene transfer into SCID repopulating cells (SRCs) and stem cells from non-human primates was improved considerably. The percentage of transduced blood and progenitor cells in the transplant recipients was between 5 and 40%, compared to below 1% in previous studies. The use of growth factor combinations was important, generally including flt-3 ligand (FL), stem cell factor (SCF), IL-3, and others, that induce cell cycle in early progenitors. [5] [6] [7] [8] [9] [10] [11] Stimulation with growth factor also enhances expression of amphotropic receptor on hematopoietic progenitors. 4 In addition, infection on the matrix component fibronectin (FN) was found to improve gene transfer into hematopoietic progenitors by colocalization of virus and target cells. 12 To overcome the restriction at receptor level, retroviral pseudotypes have been used. Pseudotypes have an envelope glycoprotein from a foreign virus and therefore an altered receptor usage. Lentiviral vectors pseudotyped with the Gprotein of vesicular stomatitis virus (VSV) were found to transduce CD34
+ cells more efficiently than the amphotropic pseudotype. 3, 13 It is, however, not clear whether gene transfer to primary stem cells can be improved by pseudotyping with VSV-G. In the recent in vivo studies mentioned, efficient gene transfer to repopulating stem cells could be achieved using amphotropic and VSV-G-pseudotypes. However, the two pseudotypes were never compared in a potential stem cell population.
In this study, we directly compared the transduction efficiency of amphotropic and VSV-G-pseudotyped retroviral vectors for CD34 + progenitors and CD34 + CD38 − cells, a subset enriched for stem cells. Our transduction protocol was similar to the ones that have recently allowed successful transduction of repopulating stem cells. Using such an optimized protocol, both pseudotypes transduced hematopoietic progenitors with similar efficiency.
Materials and methods

Isolation of progenitor cells
After informed consent, CD34
+ cells were isolated from bone marrow, leukapheresis, and cord blood samples. Mononuclear cells were isolated by Ficoll gradient centrifugation (Biochrom, Berlin, Germany) and the CD34 + cells enriched to over 98% purity by two sequential columns using the MACS progenitor cell isolation kit (Miltenyi Biotec, Bergisch-Gladbach, Germany). To isolate the CD34 + CD38 − and CD34 + CD38 + subsets, MACS-purified CD34 + cells were stained with anti-CD34 and anti-CD38 (Pharmingen, San Diego, CA, USA) and sorted on a MoFlo cell sorter (Cytomation, Fort Collins, CO, USA).
Retroviral vector production
The retroviral vector containing the cDNA for the human truncated low-affinity nerve growth factor receptor (⌬LNGFR) has been described previously.
14 The amphotropic vector (dLN-A) was packaged in GP+envAM12 cells. 15 VSV-G pseudotypes (dLN-G) were produced in the inducible packaging cell line 293GPG as described previously. 16 Titers were 2-5 × 10 6 LNGFR transferring units per ml for both pseudotypes. Virus was titered on Sc-1 mouse fibroblasts as described. 14 
Transduction protocol
Purified hematopoietic progenitor cells (1-4 × 10 4 per ml) were prestimulated in BIT Medium (Cellsystems Biotechnologie, St Katharinen, Germany) with stem cell factor (rhu SCF, 100 ng/ml, Boehringer Mannheim/Roche, Indianapolis, IN, USA), Flt-3 ligand (rhu FL, 100 ng/ml, Pepro Tech/Tebu, Frankfurt am Main, Germany) and interleukin-3 (rhu IL-3, 20 ng/ml, Boehringer Mannheim/Roche) for 44 h. Cells were then pelleted and resuspended at a density of 1 × 10 5 /ml in vector supernatants supplemented with growth factors (FL, SCF, IL-3) and incubated for 1 h at 37°C. For some transductions fibronectin (FN)-coated 6-well plates (Falcon/Becton Dickinson, Bedford, MA, USA) were used. Cells were then diluted with growth-factor supplemented BIT medium and cultured for a further 48 h.
Analysis of transduction efficiency
To determine the transduction efficiency by flow cytometry a biotinylated anti-LNGFR monoclonal antibody (kindly supplied by R Rüger, Boehringer Mannheim) in combination with fluorochrome-conjugated streptavidin (Pharmingen) was used. Flow cytometric analysis was performed on a FACScalibur (Becton Dickinson).
Results
Influence of the multiplicity of infection on the efficiency of gene transfer
Transduction efficiencies at different multiplicities of infection (MOI) were then determined for both pseudotypes. 
Effect of fibronectin fragments on gene transfer with VSV-G pseudotypes
Fibronectin can improve gene transfer with amphotropic vectors considerably. Whether fibronectin has a similar effect on VSV-G-pseudotyped vectors is not known. We have compared the transduction efficiencies of CD34 + cells for dLN-A and dLN-G on untreated and fibronectin-coated tissue culture dishes. Cells were again prestimulated for 44 h, transduced, and scored for LNGFR expression on day 4. Transduction with dLN-A was improved considerably by fibronectin (5-to 19.3-fold, mean 12.6), while the effect on gene transfer by dLN-G was far less pronounced but still significant (1-to 3.9-fold, mean 2.1, P = 0.04, Figure 2 ).
Transduction of CD34
+ CD38 − cells
The transduction efficiency for the amphotropic vector in CD34 + CD38 + and CD34 + CD38 − cells was analyzed. The latter subset is enriched in more primitive progenitors such as long-term culture initiating cells (LTC-IC) and SRC. CD34 + cells were isolated and further separated into the CD34 + CD38 + and CD34 + CD38 − fraction by FACS sorting. After 2 days of prestimulation, cells were transduced on FN with equal MOIs for both subsets (ranging from 1 to 15 between different experiments) and the transfer efficiency was then determined by flow cytometry on day D von Laer et al Figure 3 as ratios (transfer efficiency CD34
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+ CD38 + /CD34 + CD38 − ).
Gene transfer into CD34
+ CD38 − cells tended to be less efficient compared to the CD34 + CD38 + subset, but this difference did not reach statistical significance (P = 0.13).
We then tested if the dLN-G vector had an advantage over dLN-A for transduction of CD34 + CD38 − cells. Cells were prestimulated for 2 days. Half the cells were then transduced with dLN-A, the other half with dLN-G using equal MOIs for both pseudotypes (ranging from 1 to 15 + CD38 − cells did not differ significantly between the two pseudotypes. Therefore, with the transduction protocol used here, a clear advantage of the VSV-G pseudotype was not seen.
Discussion
Retroviral transduction of hematopoietic stem cell lines is restricted at the level of virus entry and this block is overcome by VSV-G pseudotypes. 3 However, in the present study, no such restriction was found in primary hematopoietic progenitors. CD34
+ cells and the CD34 + CD38 − subset, which is enriched in cells with repopulating potential, were transduced with similar efficiencies by amphotropic and VSV-G-pseudotyped vectors.
In several target cells that lack amphotropic receptor, VSV-G pseudotypes have a higher transduction efficiency. 17 In one study, gene transfer into CD34 + cells, as measured by luciferase marker gene expression, was 10-fold more efficient for VSV-G pseudotypes than with the amphotropic vector. 13 In the study described here, such a difference was not seen. This discrepancy is difficult to explain, since culture conditions and transduction protocol were not described in the previous report (published as a note). Moreover, in the previous study a lentiviral vector was used and not an MLV-derived vector as in our study. However, in agreement with our results, Yam and coworkers 18 recently found that VSV-G-pseudotyped and ampho- 
tropic vectors transduce CD34
+ PBPC with similar efficiency.
FN improved gene transfer for both pseudotypes. For amphotropic as well as for GALVenv-pseudotyped such an effect has already been described. 12, [19] [20] [21] Interestingly, the effect of FN on the transduction efficiency with VSV-G pseudotypes was far less pronounced. There are several possible explanations: (1) binding sites on FN could be saturated by G-protein not associated with infectious particles in the vector supernatant; (2) colocalization of virus and cells may not be so critical for VSV-G pseudotypes, because the receptor density does not restrict virus uptake; (3) VSV-G pseudotypes may bind to FN less efficiently than other retroviral pseudotypes. Further experiments are necessary to clarify this issue.
To determine if VSV-G-pseudotypes have a higher transduction efficiency in more primitive hematopoietic progenitors, CD34 + CD38 − cells, which are enriched in repopulating cells, were studied. In several previous reports, this population was more resistant to retroviral transduction than the more mature CD34
+ CD38 + cells. 14, 22, 23 However, if cells were cultured with growth factors, that expand immature progenitors ex vivo, no such restriction was found. 24, 25 In agreement with these more recent reports, transduction with the amphotropic vector was not restricted considerably in the CD34
+ CD38 − population in our study. Moreover, pseudotyping with VSV-G did not improve gene transfer into the CD34 + CD38 − cells. This result is a strong indication that VSV-G pseudotypes do not transduce primitive hematopoietic progenitors more efficiently than amphotropic vectors if optimized culture conditions are used.
A major problem of ex vivo studies is the heterogeneity of the primary human progenitor population. Less than 1 in 500 CD34
+ CD38 − cells has repopulating capacity for SCID mice (SRC). 26 To definitively determine whether VSV-G pseudotypes improve gene transfer to repopulating stem cells, transplantation studies will be necessary. However, considering that several groups have recently succeeded in efficiently transducing SRC with amphotropic vectors, our data predict that transduction of repopulating hematopoietic stem cells will not be improved further by the use of VSV-G pseudotypes.
